Back to top
more

Eton Pharmaceuticals (ETON)

(Delayed Data from NSDQ)

$5.94 USD

5.94
56,372

+0.03 (0.51%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $5.93 -0.01 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

by Zacks Equity Research

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

by Zacks Equity Research

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

bluebird bio (BLUE) Rides High on Its Gene Therapy Approvals

by Zacks Equity Research

bluebird's (BLUE) recent FDA approvals for its gene therapies, namely beta-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, will likely drive the top line.

Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

by Zacks Equity Research

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.

Inhibrx (INBX) Down on Updated Data From Bone Cancer Study

by Zacks Equity Research

Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.

Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 20% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 33.83% and 281.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 6.36% and 1.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -300% and 5.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -150% and 40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 7.64% and 99.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -162.50% and 69.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -8.70% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Eton Pharmaceuticals, Inc. (ETON) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.77% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 244.44% and 95.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for December 14th

by Zacks Equity Research

SNAX, ETON, AVYA, DLB, and ROCC have been added to the Zacks Rank #5 (Strong Sell) List on December 14, 2021

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -71.43% and -74.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.